FDA approves Johnson & Johnson's rare disease drug that's expected to compete with argenx and UCB

The FDA approved a new rare disease drug that Johnson & Johnson hopes can compete with established medicines — and some that are yet to be approved — and become a megablockbuster. Regulators on Wednesday gave the ...